Collaboration to Support Potential Commercialization of Intismeran Autogene CHICAGO --(BUSINESS WIRE)--Oct. 7, 2026-- Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel, potential
CHICAGO --(BUSINESS WIRE)--Oct. 1, 2026-- Tempus AI, Inc. (NASDAQ: TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid. At this year’s congress, Tempus will showcase
ECG-MR becomes the fourth FDA -cleared Tempus ECG-AI product, spanning arrhythmia, heart function, pulmonary vascular and valvular disease CHICAGO --(BUSINESS WIRE)--Sep. 28, 2026-- Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S.
CHICAGO --(BUSINESS WIRE)--Sep. 21, 2026-- Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will license Recursion’s RNA
The Initiative Will Make Available 100,000 Disease-Specific Whole Genome Sequences Paired with Longitudinal Clinical Outcomes, with a Long-Term Goal of Reaching 1 Million Genomes CHICAGO --(BUSINESS WIRE)--Sep. 11, 2026-- Tempus AI, Inc. (NASDAQ: TEM) today announced an initiative to build a
The Initiative Will Pioneer an AI Agent That Functions as an Extension of the Clinician Team, Capable of Delivering and Coordinating Cardiovascular Care Without Direct Human Intervention CHICAGO --(BUSINESS WIRE)--Sep. 9, 2026-- Tempus AI, Inc. (NASDAQ: TEM) today announced that it has been
CHICAGO --(BUSINESS WIRE)--Sep. 4, 2026-- Tempus AI, Inc. (NASDAQ: TEM) today announced that Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. ET in New York City.
ECG-PH clearance adds pulmonary hypertension to Tempus’ FDA -cleared AI products for atrial fibrillation and low ejection fraction CHICAGO --(BUSINESS WIRE)--Aug. 24, 2026-- Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S.
Tempus' multimodal foundation model offers diagnostic-grade precision for cancer detection and unlocks broader applications predicting biomarker status and patient prognosis CHICAGO --(BUSINESS WIRE)--Aug. 4, 2026-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to
CHICAGO --(BUSINESS WIRE)--Jul. 30, 2026-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended June 30, 2026. “Q2 was another exceptional quarter for us,” said Eric Lefkofsky, Founder
